Garcia-Manero and Zeidan Highlight Key Implications of the C

Drs Garcia-Manero and Zeidan discuss the significance of efficacy and safety data from the COMMANDS trial in myelodysplastic syndrome, takeaways from the subgroup analyses, and expectations around treatment sequencing in the lower-risk population.

Related Keywords

Connecticut , United States , New Haven , Houston , Texas , Guillermo Garcia Manero , Samer Zeidan , Ashling Wahner , Linkedin , Division Of Cancer Medicine , University Of Texas Md Anderson Cancer Center , Twitter , Yale School Of Medicine , Bristol Myers Squibb , Department Of Leukemia , Facebook , Hematologic Malignancies At Yale Cancer Center , Translational Research , Early Therapeutics Research In Hematology , Clinical Research Team For Leukemias , Myelodysplastic Syndromes , Cancer Medicine , Cancer Center , Yale School , Early Therapeutics Research , Clinical Research Team , Myeloid Malignancies , Hematologic Malignancies , Yale Cancer Center , Drs Garcia Manero , Bristol Myers , Apple Podcasts , Google Podcasts , Amazon Music , D , Bbs , Dhs , Commands Trial , Nct03682536 , Lower Risk Myelodysplastic Syndromes , The University Of Texas Md Anderson Cancer Center ,